Research
Adherence
Phenotype-prioritized treatment selection (SGLT2i for HF/CKD, GLP-1RA for ASCVD/Obesity) optimizes outcomes and reduces polypharmacy compared to single-disease guidelines.
Ask your doctor for a 'phenotype-first' approach. Instead of treating each condition separately, choose drugs that protect your heart, kidneys, and metabolism all at once. This can simplify your medication list and reduce side effects.
LimitedSupportsMEDIUM confidence
This review indicates that sodium-glucose cotransporter 2 inhibitors or GLP-1 receptor agonists should be prioritized based on phenotypic characteristics... Moreover, the implementation of threshold monitoring protocols is imperative in order to mitigate the risk of hypoglycemia, hypotension, and hyperkalemia.
Why this rating
Based on narrative review of multiple trials.
Source
Mechanism-guided pharmacotherapy for cardiometabolic multimorbidity: from pathophysiology to phenotype-prioritized treatment
Hezeng Dong et al. · Frontiers in Endocrinology · 2025
DOI 10.3389/fendo.2025.1724965
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors and GLP-1 receptor agonists provide multi-organ cardiorenal protection beyond glycemic control, with selection prioritized by phenotype (e.g., SGLT2i for heart failure/CKD, GLP-1RA for ASCVD/obesity).Weak
- Non-steroidal mineralocorticoid receptor antagonists (ns-MRA) like finerenone reduce cardiovascular and renal risks in T2D+CKD patients, with hyperkalemia risk manageable through monitoring.Weak
Related findings · Adherence
- Regular physical activity (at least 150 minutes/week of moderate-intensity) reduces all-cause and cardiovascular mortality by 20-30% and lowers the risk of type 2 diabetes by 25-35%.Strong
- Increasing physical activity from a sedentary lifestyle to an active one in middle adulthood significantly reduces the risk of coronary events compared to remaining sedentary.Strong
- Resistance exercise is the only intervention capable of consistently restoring muscle function and strength in sarcopenia, partially overcoming age-related anabolic resistance.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →